Suchergebnisse
9. Apr. 2024 · Core One Labs Inc. is a biotechnology company focused on developing novel psychedelic compounds for various indications. Read the latest news about its private placements, debt settlements, agreements, and research results.
21 Nachrichten in den letzten 12 Monaten. CORE ONE LABS INC-Investoren interessieren sich auch für diese News. Aktuelle Kennzahlen zu CORE ONE LABS. CORE ONE LABS INC gehört der Branche...
- (141)
Vor 3 Tagen · IRW-News: Core One Labs Inc.: Core One-Tochter Akome erzielt in der vorläufigen Phase-1-Tiermodellstudie für die Bio-Verbindung, die auf Alzheimer und Parkinson abzielt, positive...
13. Jan. 2023 · Core One Labs, a biotechnology company focused on psychedelic medicines, has acquired GMP Drug Inc., a GMP facility in Ontario, Canada. The acquisition will enable Core One to produce, research and distribute psychedelic compounds and prodrugs for clinicians, researchers and other drug developers.
Core One Labs, a biotechnology company focused on psychedelic medicines, has entered into an initial agreement with Cube Psytech to explore the potential sale or licensing of its proprietary biosynthetic psilocybin technology. The agreement could facilitate Core One's entry into the international market and expand its psychedelic solutions.
8. Dez. 2023 · Core One, leveraging its wholly-owned subsidiaries Vocan Biotechnologies Inc. (" Vocan ") and Awakened Biosciences Inc. (" Awakened" ), has successfully developed a proprietary method for the...
2. Dez. 2023 · Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods....
